Zacks Investment Research on MSN6d
Merck Inks $2B Licensing Deal With Chinese Biotech for Oral Heart Drug
Merck MRK announced that it has entered into an exclusive licensing deal with China-based Jiangsu Hengrui Pharmaceuticals ...
Merck (NYSE:MRK) Becomes Latest Big Pharma Stock to Tap China with $2B Heart Disease Drug Rights Deal
Merck (MRK) has signed a licensing agreement for a heart disease drug developed by a Chinese company in a deal worth up to $2 billion, the ...
Benzinga.com7d
Merck Partners With Hengrui Pharma In $1.77 Billion Deal For Cardiovascular Treatment
Merck gains global rights to HRS-5346, an oral Lp(a) inhibitor, excluding Greater China, under a deal with Hengrui Pharma. Hengrui Pharma gets $200M upfront, up to $1.77B in milestones ...
Global Times5d
Hengrui Pharma signs exclusive licensing agreement for its heart disease drug with Merck & Co.
Under the agreement, Hengrui Pharma has granted Merck exclusive rights to develop, manufacture, and commercialize HRS-5346 worldwide, excluding the Greater China region. Hengrui Pharma will ...
pharmaphorum2y
Merck snaps up cancer drug from China's Kelun in $1.4bn deal
Merck & Co has quietly added another drug to its immuno-oncology pipeline via an agreement with China's Sichuan Kelun Pharmaceutical, and is keeping the details close to its chest. The US pharma ...